Christina I. Herold - Concepedia

Author

Christina I. Herold

Beth Israel Deaconess Medical Center ORCID

Also Known As

C Herold, C. Herold, C. I. Herold, Christina Herold, Christina I Herold, Christina I. Herold, Christina Isabella Herold

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Massachusetts General Hospital Harvard University Lifespan

About

Christina I. Herold is an author at Beth Israel Deaconess Medical Center specializing in breast cancer, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	700
2	Health Sciences	1	1	26
3	Cell Biology	1	1	648
4	Immunology	1	1	10
5	Obstetrics	1	1	26

Christina I. Herold

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers Andrew J. Armstrong, Matthew S. Marengo, Sebastian Oltean, Molecular Cancer Research Lung MetastasesBreast OncologyPathologyTumor CellsCancer Biology	2011	648
Frequency of mutations in individuals with breast cancer referred for <scp><i>BRCA</i></scp><i>1</i> and <scp><i>BRCA</i></scp><i>2</i> testing using next‐generation sequencing with a 25‐gene panel Nadine Tung, Chiara Battelli, Brian Allen, Cancer	2014	430
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer Joyce F. Liu, Christina I. Herold, Kathryn P. Gray, JAMA Oncology	2019	218
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases Rachel A. Freedman, Rebecca Gelman, Jeffrey S. Wefel, Journal of Clinical Oncology	2016	167
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing Christina I. Herold, Vijaya Chadaram, Bercedis L. Peterson, Clinical Cancer Research	2011	79
New targets for triple-negative breast cancer. Christina I. Herold, Carey K. Anders PubMed	2013	29
Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical Outcomes Anita Mamtani, Julie J. Gonzalez, Dayna T. Neo, Annals of Surgical Oncology Tumor CharacteristicsSurgical OncologyBreast OncologyMedicineCancer Management	2016	26
A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer J.F. Liu, Christina I. Herold, Wenjie Luo, Annals of Oncology	2018	22
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation Félix Balazard, Aurélie Bertaut, Élise Bordet, JNCI Journal of the National Cancer Institute	2023	19
AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+/HER2− primary breast cancer. Mario Campone, Yvonne Dong, Bethany Ling, Journal of Clinical Oncology Breast OncologyChemoprevention StrategyPathologyPharmacotherapyAmcenestrant 200	2022	16

Page 1